Dr. Shune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6030Fax+1 913-588-4085
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 2010 - 2013
- University of MinnesotaResidency, Internal Medicine, 2007 - 2010
- Istanbul University FomClass of 2004
Certifications & Licensure
- MO State Medical License 2021 - 2026
- KS State Medical License 2014 - 2025
- American Board of Internal Medicine Hematology
Clinical Trials
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency Start of enrollment: 2021 Nov 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15 - 1 citationsComparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-02-18 - Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani
Blood. 2025-02-12
Press Mentions
- “Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple MyelomaMarch 24th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: